Gemeinschaftskrankenhaus Havelhoehe gGmbH

The medical center is at the forefront of oncology research, particularly in the treatment of non-small cell lung cancer (NSCLC) with HER2 mutations. The center's innovative approach involves the use of zongertinib (BI 1810631), which is being tested for its efficacy compared to standard treatments. This research aims to improve progression-free survival in patients with advanced stages of the disease.

• HER2 Mutation Targeting
• Progression-Free Survival Enhancement
• Advanced NSCLC Treatment

By focusing on genetic mutations, the center is paving the way for personalized cancer therapies that offer hope for improved outcomes.

In the realm of cardiology, the center is conducting pivotal research on acute heart failure (AHF). The focus is on understanding the metabolism of cardiomyocytes and the reduction of biomarkers such as lactate and NT-proBNP. This research is crucial for developing new therapeutic strategies to manage and treat heart failure effectively.

• Cardiomyocyte Metabolism
• Biomarker Reduction
• Heart Failure Management

The center's work in this area is instrumental in advancing the understanding of heart failure and improving patient care.

The center is pioneering research in gastroenterology, specifically focusing on active ulcerative colitis. A novel approach being explored is the long-term therapeutic transfer of encapsulated stool microbiome. This study aims to assess the clinical efficacy of faecal microbiota transplantation in managing the condition.

• Microbiome Therapy
• Ulcerative Colitis Management
• Long-term Therapeutic Strategies

By leveraging the power of the microbiome, the center is contributing to the development of innovative treatments for chronic gastrointestinal diseases.